Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Tuesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS opened at $0.03 on Tuesday. The stock has a 50-day moving average price of $0.03 and a 200-day moving average price of $0.04. The firm has a market cap of $1.28 million, a PE ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.78.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.